The benefit of minocycline on negative symptoms in early-phase psychosis in addition to standard care - extent and mechanism (BeneMin)
Lisiecka, Danuta M; Suckling, John; Barnes, Thomas R E; Chaudhry, Imran B; Dazzan, Paola; Husain, Nusrat; Jones, Peter B; Joyce, Eileen M; Lawrie, Stephen M; Upthegrove, Rachel; Deakin, Bill
DOI: 10.1186/s13063-015-0580-x

License: Creative Commons: Attribution (CC BY)

Citation for published version (Harvard): Lisiecka, DM, Suckling, J, Barnes, TRE, Chaudhry, JB, Dazzan, P, Husain, N, Jones, PB, Joyce, EM, Lawrie, SM, Upthegrove, R & Deakin, B 2015, 'The benefit of minocycline on negative symptoms in early-phase psychosis in addition to standard care - extent and mechanism (BeneMin): study protocol for a randomised controlled trial', Trials, vol. 16, 71. https://doi.org/10.1186/s13063-015-0580-x

Publisher Rights Statement: This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Checked October 2015

General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

Users may freely distribute the URL that is used to identify this publication.
Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
Users may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988. Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Download date: 09. Mar. 2020
The benefit of minocycline on negative symptoms in early-phase psychosis in addition to standard care - extent and mechanism (BeneMin): study protocol for a randomised controlled trial

Danuta M Lisiecka¹,²*, John Suckling¹,²,³, Thomas RE Barnes⁴,⁵, Imran B Chaudhry⁶,⁷, Paola Dazzan⁸, Nusrat Husain⁶, Peter B Jones⁵,⁹, Eileen M Joyce¹⁰, Stephen M Lawrie¹¹, Rachel Upthegrove¹²,¹³ and Bill Deakin⁶,¹⁴

Abstract

Background: Negative symptoms of psychosis do not respond to the traditional therapy with first- or second-generation antipsychotics and are among main causes of a decrease in quality of life observed in individuals suffering from the disorder. Minocycline, a broad-spectrum tetracyclic antibiotic displaying neuroprotective properties has been suggested as a new potential therapy for negative symptoms. In the two previous clinical trials comparing minocycline and placebo, both added to the standard care, patients receiving minocycline showed increased reduction in negative symptoms. Three routes to neuroprotection by minocycline have been identified: neuroprotection against grey matter loss, anti-inflammatory action and stabilisation of glutamate receptors. However, it is not yet certain what the extent of the benefit of minocycline in psychosis is and what its mechanism is. We present a protocol for a multi-centre double-blind randomised placebo-controlled clinical trial entitled The Benefit of Minocycline on Negative Symptoms of Psychosis: Extent and Mechanism (BeneMin).

Methods: After providing informed consent, 226 participants in the early phase of psychosis will be randomised to receive either 100 mg modified-release capsules of minocycline or similar capsules with placebo for 12 months in addition to standard care. The participants will be tested for outcome variables before and after the intervention period. The extent of benefit will be tested via clinical outcome measures, namely the Positive and Negative Syndrome Scale score, social and cognitive functioning scores, antipsychotic medication dose equivalent and level of weight gain. The mechanism of action of minocycline will be tested via blood screening for circulating cytokines and magnetic resonance imaging with three-dimensional T1-weighted rapid gradient-echo, proton density T2-weighted dual echo and T2*-weighted gradient echo planar imaging with N-back task and resting state. Eight research centres in UK and 15 National Health Service Trusts and Health Boards will be involved in recruiting participants, performing the study and analysing the data.

Discussion: The BeneMin trial can inform as to whether in minocycline we have found a new and effective therapy against negative symptoms of psychosis.

(Continued on next page)
Background

Negative symptoms in psychosis

Psychosis leads to a significant decrease in a person’s quality of life [1], with negative symptoms contributing the most to impaired functional outcome [2]. Negative symptoms - reduction in emotional and social responsiveness, motivation, speech and movement [3] - respond the least to known antipsychotic treatments among all psychotic symptoms [4]. Their initial severity, together with duration of untreated psychosis (DUP) and cognitive impairments, is the best predictor of an individual’s subsequent impairment in quality of social and occupational functioning [5]. Their positive correlation with DUP links their aetiology to a neuropathic process progressing with continuance of untreated psychosis [6-11]. This hypothesis has led to an interest in neuroprotection during early stages of psychosis as a potential therapeutic target for negative symptoms.

Efficacy of minocycline for negative symptoms of psychosis

A broad-spectrum tetracyclic antibiotic, minocycline has neuroprotective properties, which could prevent the accumulation of negative symptoms in psychosis [12-15] while improving the prognosis of neurodegenerative diseases and traumatic or ischaemic central nervous system (CNS) insults [16-19]. Due to its lipophilic properties, it has exceptional potential for blood-brain barrier penetration [20]. It is also marked by its relatively low toxicity [21].

Two double-blind randomised placebo-controlled studies of minocycline as a neuroprotective agent for negative symptoms of psychosis have been completed [14,15]. The first was a 2-centre study in Brazil and Pakistan supervised by the University of Manchester with 144 participants [14]. The second, completed in Tel Aviv, Israel, recruited 70 relapsed patients with schizophrenia [15]. Both studies found significant treatment effects on negative symptoms with adjunctive minocycline. In the first trial, significant treatment effects were observed at 6 months, and in the second trial at 3 months. Furthermore, the 2-centre trial demonstrated that therapeutic effects were sustained at 12 months. No other trials investigating the efficacy of minocycline for negative symptoms have been registered in UK or US databases. However, to assess the extent and mechanism of the benefit of minocycline for negative symptoms in psychosis, a trial with a larger cohort is needed.

Mechanism of action of minocycline on negative symptoms

Although the effectiveness of minocycline in treating negative symptoms has been identified, its mechanism of action remains unresolved [22]. Three possible mechanisms of action have been postulated:

1) Neuroprotection against grey matter loss: minocycline may directly prevent neurodegeneration of grey matter in individuals with psychosis. Its neuroprotective properties have been shown in stroke [21,23], Parkinson’s disease [24,25], cerebral ischaemia, amyotrophic lateral sclerosis, Huntington’s disease and multiple sclerosis [26]. In psychosis, loss of grey matter occurs early in the course of the disease [27-30], is associated with DUP [31] and predicts diminished functional outcome [32]. By preventing grey matter loss, minocycline may limit negative symptoms.

2) Anti-inflammatory action: the anti-inflammatory properties [33,34] of minocycline may prevent neural changes associated with the action of microglia and cytokines in psychosis [35]. The inflammatory response as a mechanism of schizophrenia has been suggested by studies demonstrating microglial activation [35,36]. The gene variants associated with risk of schizophrenia have been linked to increased levels of circulating cytokines [37]. A correlation between negative symptoms and levels of IL-10 cytokine has been observed in untreated psychosis [38]. Increased levels of IL-6 appears in medication-naïve patients with first episode of psychosis [39] and acutely relapsed inpatients [40], whereas elevated levels of IL-6 at the age of 9 doubles the risk of developing psychosis later in life [41]. Minocycline may reduce cytokine levels during psychosis thereby limiting negative symptoms.

3) Stabilisation of N-methyl-D-aspartate (NMDA) glutamate receptors: minocycline may improve impaired function of the NMDA glutamate receptor which is thought to display impairment in schizophrenia [42]. Ketamine, which blocks NMDA receptors and causes dysfunctional release of
glutamate [43,44], evokes schizophrenia-like negative symptoms in healthy individuals [45]. Minocycline can block ketamine action [46], thus potentially stabilising glutamate release in NMDA receptors [47]. Minocycline may limit negative symptoms either through direct action on glutamate release or through prevention of glutamate neurotoxicity on neuronal branching and glial cells [48]. Although not observable in vivo, this can be examined by the association between NMDA receptors and working memory [49,50].

The three mechanisms of action of minocycline may operate separately or jointly. Each represents a potential target for neuroproteetion, effective only when neurodegenerative processes are active and their adverse effects limitable. Thus, minocycline is likely to be observed as being most effective in the early stages of psychosis.

Benefits and risks of treatment with minocycline
The treatment of psychosis with minocycline may benefit patients by reducing their negative symptoms and, consequently, their difficulties in social and occupational function [5]. This treatment may also reduce the dose of antipsychotic drugs (APDs) necessary to stabilise a patient’s health, thus decreasing potential side-effects of APDs such as weight gain [4]. Finally, new targets for the treatment of psychosis may be discovered [51], which could elucidate the pathophysiology of psychosis and potential biomarkers of increased risk of developing it.

Treatment with minocycline has been associated with vestibular disturbances, gastro-intestinal upset and fatigue [52-54]. Nevertheless, our previous study [14] did not find any such link. Minocycline use has also been associated with the development of a systemic lupus erythematosus - like syndrome [55] with, however, an estimated incidence of 8.8 cases per 100,000 person-years [56]. Patches of discolouration on teeth and skin have also been observed during long-term therapy with minocycline [57,58]. In our previous study [14], three people in each treatment arm reported hyper-pigmentation, but only those in the minocycline arm withdrew from the trial. This was the only noted side-effect withdrawal.

The risks and side-effects observed during minocycline treatment are less severe than those associated with the available antipsychotic drugs, which include extrapyramidal symptoms [59-61], metabolic problems and sedation [62-68]. It is estimated that adding minocycline to standard treatment will have similar effect-size as was observed with a benefit of second-generation APDs over older APDs [62,69].

Rationale and aims of the BeneMin trial
Finding an effective treatment for negative symptoms in psychosis is of paramount importance due to their role in post-morbid functional outcome [2]. Minocycline has been identified as a potential agent for reducing negative symptoms [14,15]. Therefore, in BeneMin we will investigate the extent and mechanism of action of minocycline on negative symptoms in psychosis. Additionally, we will test whether characteristics such as premorbid and current IQ, DUP and cytokine genotype predict the response to minocycline.

Effectiveness hypotheses (EHs)

EH1) Added to the standard therapy, minocycline administered during the acute phase of psychosis limits development of negative symptoms in comparison to placebo.

EH2) Minocycline reduces side-effects associated with standard therapy such as weight gain in comparison to placebo.

EH3) Reduction of negative symptoms leads to improvement in function and life quality in patients treated with minocycline in comparison to placebo.

Mechanistic hypotheses (MHs)

MH1) In comparison to placebo, minocycline reduces grey matter degeneration, which occurs particularly during the early acute phase of the disease. The reduction in grey matter degeneration is observed mainly in the frontal lobes and is associated with reduction of negative symptoms.

MH2) In comparison to placebo, minocycline diminishes inflammatory action in the CNS thereby reducing negative symptoms. Decreased numbers of circulating cytokines in peripheral blood, and potentially reduced grey and white matter neurodegeneration and micro lesions in the CNS, are observed as the result of minocycline treatment.

MH3) In comparison to placebo, minocycline improves function of NMDA glutamate receptors and restores optimal levels of glutamate in the CNS, observed through improved cortical function of working memory. The improvement may be a direct result of minocycline action and may cease after the treatment stops or continue through the neuroprotective action of optimal glutamate levels.

Methods

Study design
BeneMin is a double-blind, randomised, placebo-controlled clinical trial investigating the extent and mechanism of action of minocycline on negative symptoms of psychosis in addition to standard APD therapy. Participants in an acute psychotic phase will be randomly allocated either to the minocycline or to the placebo arm and
continue to receive the assigned treatment for 12 months. Both participants and investigators will be blind to treatment group, which will be guaranteed by a direct data-entry, digital database (OpenCDMS system). Separately, participants will be asked to donate fully-anonymised DNA for genotyping of the interleukin 6 (IL-6) gene [70] and for future investigations. The study will be conducted at eight research centres, and led by the University of Manchester (Table 1).

The EHs will be tested via clinical outcome variables: levels of negative and positive symptoms of psychosis, observed side-effects and subsequent quality of life. The MHS will be examined via biomarker outcome variables obtained through blood screening for circulating cytokines and magnetic resonance imaging (MRI). In addition to treatment effectiveness, mediators of treatment response such as DUP, cognitive function and IL-6 gene variants will be assessed.

A pre-post treatment design will be used with baseline measurements of the outcome variables taken before commencement of treatment (screening and randomisation visits) and repeated soon after the treatment has finished (month 12 visit). Clinical outcome variables will also be measured between the pre- and post-treatment assessments (month 2, 6 and 9 visits) to capture possible early therapeutic effects of minocycline. The last assessment will be performed 3 months after the participant has finished their treatment (that is 15 months post-randomisation).

Participants

Eligibility criteria

The BeneMin trial will recruit participants in an acute phase of psychosis within 5 years from their first diagnosis. The detailed inclusion and exclusion criteria of the participants are presented in Figure 1.

Sample size and recruitment settings

We aim to enrol a total of 226 eligible participants among the 8 research centres. The predicted number of participants remaining in the trial at each stage is presented in the CONSORT diagram in Figure 2. The calculations are based on our previous study of minocycline [14] and a calibration study we performed before this trial [71]. The number of participants was chosen to ensure feasibility of the analysis of post-treatment MRI scans. To meet our recruitment aims we will collaborate with Local Research Networks of the English National Institute for Health Research and Scottish Mental Research Networks. The patients will be recruited via 15 National Health Service (NHS) Trusts and Health Boards (Table 1).

Table 1 Research centres involved in BeneMin with the corresponding National Health Service (NHS) Trusts, Health Boards and magnetic resonance imaging (MRI) centres

| Research centres       | NHS trusts and health boards | MRI centres                                      |
|------------------------|------------------------------|-------------------------------------------------|
| University of Manchester | • Manchester Mental Health and Social Care Trust  |
|                        | • Greater Manchester West Mental Health NHS Foundation Trust |
|                        | • Pennine Care NHS Foundation Trust (PIC) |
| Lancashire Early Intervention Services | • Lancashire Care NHS Foundation Trust |
| Cheshire and Wirral Partnership Early Intervention in Psychosis Service | • Cheshire and Wirral Partnership NHS Foundation Trust |
| University of Cambridge | • Cambridge and Peterborough NHS Foundation Trust |
|                        | • Norfolk and Suffolk NHS Foundation Trust (PIC) |
| University College London | • West London Mental Health NHS Trust |
|                        | • Central and North West London NHS Foundation Trust |
|                        | • Camden and Islington NHS Foundation Trust |
|                        | • Barnet, Enfield and Haringey Mental Health Trust |
| King’s College London | • South London and Maudsley NHS Foundation Trust |
| University of Edinburgh | • NHS Lothian |
|                        | • NHS Fife (PIC) |
| University of Birmingham | • Birmingham and Solihull Mental Health NHS Foundation Trust |

PIC, patient identification centre.
Suitable candidates will first be approached by delegated members of their clinical teams, who will assess each candidate’s eligibility and ask for their permission to be contacted by a project’s research assistant (RA). Eligible candidates will receive the BeneMin patient information leaflet explaining the trial. After expressing interest they will be approached by the RA who will again verify eligibility. Subsequently, the RA will obtain the candidate’s informed consent for participation in the trial, having verified that the candidate fully understands what is involved. Separate consent will be obtained for donating DNA to the bio-bank at the University of Manchester.

Withdrawal
At any time a participant can withdraw their consent for participation without giving reasons. The participant will be given an opportunity to discuss the reason for withdrawal and any adverse events (AE). If possible, the participant will be assessed by the investigator. Any potential AE will be followed up by the resident medical officer (RMO). If the participant withdraws their consent...
at any time beyond 6 months of treatment they will be asked to complete the full post-treatment assessment, followed 3 months later by the post-trial assessment. Their results will be included in the main analysis. The detailed withdrawal criteria are presented in Figure 1.

Randomisation procedure
After stratification by the research centre, permuted block randomisation integrated with the OpenCDMS system will be used to allocate participants to the treatment arm. After an investigator has requested randomisation for a participant, the OpenCDMS will use the algorithm to allocate the participant to the treatment arm. Subsequently, it will notify a local pharmacy regarding the serial number of a medication kit to use. Participant's allocation to the study arm will be known only to the OpenCDMS system.

Planned intervention
Participants will take capsules containing either 100 mg minocycline (modified-release) or matching placebo, 2 per day for the first 2 weeks and then 3 per day for the remainder of the 12-month treatment period in addition to standard therapy. The maximum dose of modified-release minocycline is 3 × 100 mg per 24 hours. Minocycline and placebo will be manufactured, controlled and distributed to the Trusts' pharmacies by Catalent, Bolton, UK, in accordance with the requirements of the Medicines and Healthcare Products Regulatory Agency (MHRA).

Clinical outcome measures
We will test hypotheses of minocycline efficacy by assessing changes in primary and secondary clinical outcome measures over treatment.

Primary clinical outcome
Severity of negative symptoms of psychosis as measured by the negative symptoms subscale of the Positive and Negative Syndrome Scale (PANSS), an instrument commonly used to assess the efficacy of treatment in schizophrenia [72] consisting of a positive symptoms subscale, a negative symptoms subscale and a general psychopathology subscale [73].

Secondary clinical outcomes
1) Body weight and body mass index [74] as a measure of weight gain, a side-effect of the standard APD therapy.
2) Severity of global and positive symptoms of psychosis as measured by the full PANSS and the PANSS positive symptoms subscale.
3) General and social function as measured by:
   - Global Assessment of Functioning from the Diagnostic and Statistical Manual, fourth edition (DSM-IV) [75,76], a scale assessing psychological, social and occupational function on a hypothetical continuum of health and illness;
   - the Social Functioning Scale [77], a self-rating scale assessing social functioning in domains such as social engagement, interpersonal behaviour, pro-social activities, independence or employment.
4) Cognitive function as measured by:
- a short Wechsler Adult Intelligence Scale III for patients with schizophrenia [78], consisting of the information, block design, arithmetic and digit-symbol subtests. This will provide a measure of current IQ and processing speed [79];
- the Wechsler Test of Adult Reading [80], a reading test which estimates premorbid IQ [81];
- Verbal fluency requiring individuals to generate words in response to phonetic or semantic criteria [82];
- the Auditory-Verbal Learning Task [83-85], a test of word list learning and recall.

5) APD dose expressed in chlorpromazine equivalent units [86], assessing the dose of APD required for the patient's stabilisation.

Biomarker outcome measures
We will examine the mechanism of action of minocycline by assessing changes in primary and secondary biomarker outcome measures over treatment. The biomarker outcomes will be measured via cytokine blood screening and MRI of the brain.

Cytokine blood screening
A blood sample from the participant will be collected into an EDTA tube during a screening visit. Portions of plasma will be separated from the sample for measurement of the cytokine markers associated with inflammatory response in previous studies, namely, IL-6 [87], interleukin-1 receptor antagonist (IL-1RA) [88], monocyte chemotactic protein 1 (MCP-1/CCL2) [89] and C-reactive protein (CRP) [90]. Measurements of IL-6, IL-1RA and MCP-1 will follow a method applied in previous studies of stroke [91,92] and will use multiplex (Luminex®, Manchester, UK) assays. For assessment of CRP level, a sensitive immunoassay will be used [93]. The lowest value among the markers will be classified as the baseline measure of cytokine concentration. Successful blood samples will be collected, and the cytokine tests repeated at month 6, post-treatment (month 12) and post-trial (month 15) visits.

Multi-centre magnetic resonance imaging
Three MRI sequences will be performed for each participant pre-treatment (randomisation visit) and post-treatment (12 month visit): three-dimensional T1-weighted rapid gradient-echo (MPRAGE/SPGR); proton density T2-weighted dual echo (PD/T2); and T2*-weighted gradient echo planar imaging (EPI) with N-back task and resting state. MPRAGE/SPGR, a high-resolution structural scan, will be used to assess volume and, thus, neurodegeneration of grey matter. PD/T2 will measure the volume of grey and white matter and of neuro-inflammatory lesions, and will be applied to perform multi-channel texture analysis [94], thus supporting the measurements of neuro-inflammation. EPI N-back via blood-oxygenation-level-dependent (BOLD) contrast will be used to test the neural function associated with the working memory network (dorsolateral-prefrontal, anterior cingulate and parietal cortices) [95] and, thus, NMDA receptors [49,50], whereas EPI resting state will be applied to observe the default network (medial temporal, medial prefrontal and posterior cingulate cortices) [96,97]. Both sequences will be used to examine functional connectivity, and be merged at acquisition into one sequence to test endogenous neural dynamics recovery from cognitive effort [98].

N-back task In the N-back task, a well-established method for observing the working memory network [99], the participant presses a button corresponding to the number observed N images previously. The numbers will range from 1 to 4 and the participant will hold a 4-button response box in their right hand. The task will consist of 3 types of blocks, 0-back, 1-back, 2-back, each repeated 5 times in quasi-randomised fashion (the same randomised pattern for each participant). Each block will contain an instruction image (3,750 ms) followed by 15 quasi-randomised trials comprising an image presenting the number (250 ms) and a blank image (1,500 ms) (Figure 3). The response can be given when either the number or the blank image are presented. Reaction times and response accuracy are recorded. After the task has finished an image will appear instructing the participant to close their eyes for the remaining part of the sequence.

Multi-centre MRI reproducibility Multi-centre imaging studies are an effective way to reach a target sample size in a clinical trial within a manageable time-frame. However, due to technical and setting differences between MRI scanners, the question of reproducibility and comparability of data arises. In BeneMin the MRI data will be collected in six MRI centres (Table 1) via six 3T MRI scanners, including two Philips Achieva (Philips Medical Systems, Best, Netherlands), two Siemens Trim Trio, one Siemens Verio (Siemens Medical Systems, Erlangen, Germany) and one GE Signa (General Electric, Milwaukee, WI, USA). Due to technical differences between scanners, a direct replication of scanning parameters would not result in functionally equivalent MRI protocols. Therefore, to develop BeneMin MRI protocols we have applied expertise established by the Alzheimer's disease neuroimaging initiative (ADNI) [100], a multicentre imaging project aiming at standardisation of MRI across sites and manufacturers, and conducted a
calibration study [71] prior to the trial. The calibration study, in which 12 healthy volunteers were scanned repeatedly in 5 different MRI centres with a protocol similar to ours, showed that between-centre differences accounted for 10% of variation in structural MRI and less than 10% in functional MRI, whereas centre-by-individual interaction was on the level of < 5%. In BeneMin the specifications for each sequence are:

1) **MPRAGE/SPGR**: voxel size of approximately 1 × 1 × 1 mm$^3$, phase encode on the anterior-posterior plane, whole brain recorded;
2) **PD/T2**: voxel size of approximately 1 × 1 × 3 mm$^3$, phase encode on the right-left plane, whole brain recorded;
3) **EPI**: TR = 2,000 ms, 748 three-dimensional volumes, voxel size of approximately 3 × 3 × 4.5 mm$^3$, slices aligned to AC-PC axis, phase encode on the anterior-posterior plane, whole brain recorded.

These parameters have been fixed as their variations cannot easily be compensated during analysis. After these specifications were incorporated, each MRI centre developed the remaining parameters of the local BeneMin MRI sequences based on standardised protocols of ADNI complemented by the centre's expertise. The protocols thus developed will be used in BeneMin, and are presented in Table 2.

**Primary biomarker outcomes**
1) Medical prefrontal grey matter volume (MH1).
2) Circulating cytokine IL-6 concentration (MH2).
3) Dorsolateral-prefrontal cortex BOLD response, accuracy and functional connectivity in N-back task (MH3).

**Secondary biomarker outcomes**
1) Total and other regional grey matter volumes (MH1).
2) Volume and multi-channel features of grey and white matter as measured by PD/T2 and of neuro-inflammatory lesions, and concentration of the remaining cytokine markers (MH2).
3) Functional connectivity and the distribution of Hurst exponent of fMRI noise in resting state (MH3).

**Side-effects and adverse events**
Possible side-effects and potential co-morbidities will be recorded. Depression will be assessed with self-rating Calgary Depression Scale for Schizophrenia [101], extrapyramidal symptoms with the Simpson-Angus Scale [102], the Barnes Akathisia Rating Scale [103], the Abnormal Involuntary Movements Scale [104] and APD subjective side-effects with the Antipsychotic Non-Neurological Side-Effects Rating Scale [105]. The seven-point adherence to treatment scale will be also used [106].
### Table 2 Reproducibility and comparability of local BeneMin magnetic resonance imaging (MRI) protocols and N-back presentation

| MRI scanner                  | Wolfson Brain Imaging Centre Cambridge | MRI facility in Salford Royal NHS Foundation Trust | Wellcome Trust Centre for Neuroimaging UCL | Centre for Neuroimaging Sciences KCL | Clinical Research Imaging Centre Edinburgh | Birmingham University Imaging Centre |
|------------------------------|---------------------------------------|--------------------------------------------------|--------------------------------------------|--------------------------------------|-------------------------------------------|-------------------------------------|
| Field strength (Tesla)       | Siemens Trio                         | Philips Achieva                                  | Siemens Trio                              | GE                                   | Siemens Verio                             | Philips Achieva                      |
| Head Coil                    | 3 T                                   | 3 T                                              | 3 T                                        | 3 T                                  | 3 T                                       | 3 T                                 |
| MPRAGE/SPGR time             | 9:14                                  | 10:52                                            | 9:14                                       | 10:19                                | 9:14                                      | 10:52                               |
| PD/T2 time                   | 5:08                                  | 5:33                                             | 5:08                                       | 4:49                                  | 5:08                                      | 5:33                                 |
| EPI time                     | 25:02                                 | 25:04                                            | 25:00                                      | 25:04                                 | 25:02                                     | 25:08                               |
| MPRAGE/SPGR voxel size FH/IS (mm) | 1                                     | 1                                               | 1                                          | 1                                     | 1                                         | 1                                   |
| MPRAGE/SPGR voxel size AP (mm) | 1                                     | 1                                               | 1                                          | 1                                     | 1                                         | 1                                   |
| MPRAGE/SPGR voxel size RL (mm) | 1                                     | 1.2                                             | 1.2                                        | 1.2                                   | 1.2                                       | 1.2                                 |
| PD/T2 voxel size AP (mm)     | 0.9                                   | 0.9                                             | 0.9                                        | 0.9                                   | 0.9                                       | 0.9                                 |
| PD/T2 voxel size RL (mm)     | 0.9                                   | 0.9                                             | 0.9                                        | 0.9                                   | 0.9                                       | 0.9                                 |
| PD/T2 voxel size FH/IS (mm)  | 3                                     | 3                                               | 3                                          | 3                                     | 3                                         | 3                                   |
| EPI voxel size RL (mm)       | 3                                     | 3                                               | 3                                          | 3.3                                   | 3                                         | 3                                   |
| EPI voxel size AP (mm)       | 3                                     | 3                                               | 3                                          | 3.3                                   | 3                                         | 3                                   |
| EPI voxel size FH/IS (mm)    | 4.5                                   | 4.5                                             | 4.5                                        | 4.5                                   | 4                                         | 4.5                                 |
| FOV MPRAGE/SPGR FH/IS (mm)   | 256                                   | 256                                             | 256                                        | 260                                   | 256                                       | 256                                 |
| FOV MPRAGE/SPGR AP (mm)      | 256 (240)                             | 256 (240)                                       | 256 (240)                                 | 260                                   | 256 (240)                                 | 240                                 |
| FOV MPRAGE/SPGR RL (mm)      | 192                                   | 204                                             | 192                                        | 204                                   | 176                                       | 204                                 |
| FOV PD/T2 AP (mm)            | 240                                   | 240                                             | 240                                        | 240                                   | 240                                       | 240                                 |
| FOV PD/T2 RL (mm)            | 240 (214)                             | 240 (210)                                       | 240 (214)                                 | 240                                   | 240 (214)                                 | 210                                 |
| FOV PD/T2 FH/IS (mm)         | 144                                   | 144                                             | 144                                        | 144                                   | 144                                       | 144                                 |
| FOV EPI RL (mm)              | 192                                   | 192                                             | 192                                        | 211                                   | 220                                       | 192                                 |
| FOV EPI AP (mm)              | 192                                   | 192                                             | 192                                        | 211                                   | 220                                       | 192                                 |
| FOV EPI FH/IS (mm)           | 126                                   | 126                                             | 126                                        | 126                                   | 129                                       | 175.5                               |
| Slice plane MPRAGE/SPGR      | Sagittal                              | Sagittal                                        | Sagittal                                   | Sagittal                              | Sagittal                                   | Sagittal                            |
| Slice plane PD/T2            | Transverse                           | Transverse                                      | Transverse                                 | Transverse/axial                       | Transverse                                 | Transverse                          |
| Slice plane EPI              | Transverse                           | Transverse                                      | Transverse                                 | Transverse/axial                       | Transverse                                 | Transverse                          |
| EPI acquisition              | Interleaved                          | Interleaved                                     | Interleaved                                | Interleaved                           | Interleaved                                | Interleaved                         |
| Number of slices for MPRAGE/SPGR | 176                                   | 170                                             | 160                                        | 170                                   | 160                                       | 170                                 |
| Number of slices for PD/T2   | 48                                    | 48                                              | 48                                         | 48                                    | 48                                        | 48                                  |
| Number of slices for EPI     | 28                                    | 39                                              | 28                                         | 28                                    | 26                                        | 39                                  |
| Number of volumes for EPI    | 748                                   | 748                                             | 748                                        | 748                                   | 748                                       | 748                                 |
| Fold-over/phase encoding direction MPRAGE/SPGR | A >> P | A >> P | A >> P | P >> A | A >> P | A >> P |
| Fold-over/phase encoding direction PD/T2 | R >> L | R >> L | R >> L | L >> R | R >> L | R >> L |
| Fold-over/phase encoding direction EPI | A >> P | A >> P | A >> P | P >> A | A >> P | A >> P |
| TE MPRAGE/SPGR (ms)          | 2.98                                  | Shortest (3.1)                                  | 2.91                                       | Min Full                               | 2.98                                      | 3.1                                 |
Additionally, any AE such as occurrence of an undesirable medical condition or deterioration of an existing medical concern will be recorded throughout the treatment duration and the post-trial period.

Assessment schedule
Each participant will undergo seven assessment sessions, which will include the screening, the pre- and post-treatment assessments, and the sessions between onset and completion of treatment. The detailed measurements taken during each session are presented in Table 3.

Analysis
Statistical analysis
A single round of analysis will be undertaken after all outcome results have been collected. Treatment effects will be assessed using the intention-to-treat method unless a significant amount of non-adherence to treatment is observed, in which case the complier-average causal effect method will be applied. In both cases non-adherence will be accounted for, since both methods allow for missing data via either inverse probability weights [107,108] or maximum likelihood estimation [109,110], and non-adherence is likely to correlate with withdrawals. Group differences in outcomes and mediators of treatment response will be assessed via a random effects model for longitudinal data, whereas MHs will be tested with instrumental variable methods [111].

MRI analysis
All MRI scans will be visually inspected for quality and possible acquisition artefacts. Subsequently, each scan will undergo standardised modality-specific temporal and spatial pre-processing:

1) MPRAGE/SPGR and PD/T2: brain tissue extraction, segmentation via scan-specific tissue priors, non-linear registration to the Montreal Neurological Institute 152 (MNI) standard space [112], smoothing with an isotropic Gaussian kernel;
2) EPI: motion and slice-timing correction, brain tissue extraction, non-linear co-registration with MNI-registered MPRAGE/SPGR, smoothing with an isotropic Gaussian kernel, intensity normalisation, high pass temporal filter.

For both MPRAGE/SPGR and PD/T2, voxel-based morphometry analysis will be performed [113], with additional lesion count in PD/T2 [114]. Texture features identified as neuro-inflammation markers in multiple sclerosis [94] will be measured in PD/T2. In EPI a general linear model will be used to model the BOLD signal [115]. Additionally, for the EPI resting state, the Hurst exponent will be extracted [116]. Group comparisons for all measures will be performed for the whole brain and for the regions of interest defined as belonging to positive and negative task networks [95-97] and located via MNI Atlases [117]. A mixed effects model for repeated measures will be used to evaluate treatment effectiveness.
defined as interaction between treatment arm and time. Additionally, a partial least squares model will be applied to identify brain structures and activation patterns associated with the extent of symptomatic change. Furthermore, seed-based correlations of voxel time-series will be used in EPI to establish treatment effects on functional connectivity of the positive and negative task networks [118]. All MRI analyses will be performed via non-parametric

| Table 3 Purpose and schedule of assessments in BeneMin |
|---------------------------------------------------------|
| **Screening (Pre-treatment)** | Randomisation | Month 2 | Month 6 | Month 9 | Month 12 (Post-treatment) | Month 15 (Post-trial) |
| Inclusion and exclusion criteria checklist | EM | | | | | |
| Case-note diagnostic checklist | EM | | | | | |
| Diagnostic and eligibility checklist | EM and CO | | | | | |
| Mini-International Neuropsychiatric Interview | EM and CO | CO | CO | CO | CO | CO |
| Positive and Negative Syndrome Scale | EM and CO | CO | CO | CO | CO | CO |
| Wechsler Adult Intelligence Scale III; 4 subtest short form | EM and CO | | CO | | CO | |
| Wechsler Test of Adult Reading | EM and CO | | | | | |
| Verbal fluency | EM and CO | | | | | |
| Auditory-Verbal Learning Task | EM and CO | | | | | |
| Medication treatment history | EM and CO | CO | CO | CO | CO | CO |
| Pregnancy urine dipstick test | EM | WCM | WCM | WCM | WCM | WCM |
| Drug urine screening test | EM | | | | | |
| Drug use questionnaire | EM | WCM | WCM | WCM | WCM | WCM | SCo |
| Blood laboratory screening for kidney and liver function | EM | | | | WCM | |
| Blood pressure and heart rate | EM | | | | WCM | SCo |
| MRI screening questionnaire | EM | | | | WCM | |
| Duration of untreated psychosis | RP | | | | | |
| Body weight and body mass index | | CO | CO | CO | CO | |
| Global Assessment of Functioning | | CO | CO | CO | CO | CO |
| Social Functioning Scale | | CO | CO | CO | CO | |
| MRI scanning | | BO | BO | BO | BO | |
| Blood cytokine screen test | | BO | BO | BO | BO | |
| Saliva Oragene kit for DNA donation | | RP | | | | |
| Withdrawal criteria checklist | | WCM | WCM | WCM | WCM | WCM |
| Calgary Depression Scale for Schizophrenia | SCo | SCo | SCo | SCo | SCo | SCo |
| Simpson and Angus Scale | SCo | SCo | SCo | SCo | SCo | SCo |
| Barnes Akathisia Scale | SCo | SCo | SCo | SCo | SCo | SCo |
| Abnormal Involuntary Movements Scale | SCo | SCo | SCo | SCo | SCo | SCo |
| Antipsychotic Non-Neurological Side-Effects Rating Scale | SCo | SCo | SCo | SCo | SCo | SCo |
| 7-point compliance scale | | AT | AT | AT | | |

EM, eligibility measure; CO, clinical outcome; RP, response predictor; BO, biomarker outcome; WCM, withdrawal criteria measure; SCo, side-effects and co-morbidity; AT, adherence to treatment.

Intersections between lines and columns show if the test took place during the visit (cells containing an abbreviation). Abbreviations explicate the reason why the test was performed at a particular stage of the trial and how the particular measure fits into statistical design of the study.
testing, with appropriate corrections for multiple comparisons [119].

Ethics approval and research sponsor
The study design and the described procedures have been approved by the National Research Ethics Service Committee North West - Greater Manchester Central (REC reference number: 11/NW/0218). The following local Research and Development departments of NHS Trusts and Health Boards after being presented with the aforementioned approval agreed to host the study: the Manchester Mental Health and Social Care Trust Research and Innovation Office, the Pennine Care NHS Foundation Trust Quality Assurance, Research and Innovation Unit, the Lancashire Care NHS Foundation Trust Research Department, the Cheshire and Wirral Partnership NHS Foundation Trust Academic Unit, the Cambridgeshire and Peterborough NHS Foundation Trust Research and Development Department, the Norfolk and Suffolk NHS Foundation Trust Research and Development Office, the UCL/UCLH Joint Research Office, the North Central London Research Consortium, the South London and Maudsley/IoPPN Research and Development Office, the NHS Lothian Academic and Clinical Central Office for Research and Development, the NHS Eife Research and Development Resource Centre and the Birmingham and Solihull Mental Health Foundation NHS Trust Research and Development Department. The Manchester Mental Health and Social Care Trust is the research sponsor and will be responsible for monitoring, audit and pharmacovigilance of the trial. The trial has the approval of MHRA.

Discussion
Minocycline has the potential to improve the treatment of negative symptoms in psychosis and thereby protect premorbid levels of functioning and consequently the quality of life for many patients. The medication has low toxicity and is not expensive to manufacture, hence it could be a straightforward addition to standard care. Furthermore, minocycline may reduce the dose of antipsychotic drugs necessary to stabilise a patient’s condition and thus limit side-effects associated with standard antipsychotic therapy.

Therapy with minocycline can potentially prevent irremovable neurodegenerative changes observed in the early stages of psychosis, which are proposed as a cause of negative symptoms. If the mechanism of action of minocycline is revealed, new targets for therapy of psychosis will be established and novel medications with clinical properties associated with the mechanism may be developed. Discovering the mechanism could also elucidate a neural basis of psychosis itself.

BeneMin as a multi-site clinical trial will evaluate the extent and mechanism of efficacy of minocycline for negative symptoms in a manageable time-frame. However, the multi-site character of BeneMin raises an issue of reproducibility and comparability of the data. Therefore, standardisation of procedures such as MRI and compatible training for the data collectors will be of key importance. On the other hand, recruiting participants from many geographical locations increases ecological validity of the sample which in turn helps with generalisation of the findings.

Trial status
The trial is ongoing. Participants are currently being recruited.

Abbreviations
ADNI: Alzheimer's disease neuroimaging initiative; AE: adverse event; APD: antipsychotic drug; BOLD: blood-oxygenation-level-dependent; CNS: central nervous system; CRP: C-reactive protein; DSM-IV: Diagnostic and Statistical Manual, fourth edition; DUP: days of untreated psychosis; EHS: effectiveness hypotheses; EPI: echo planar imaging; IL-1RA: interleukin-1 receptor antagonist; IL-6: interleukin 6; MCP-1: monocyte chemotactic protein 1; MHs: mechanistic hypotheses; MHRA: The Medicine and Healthcare Products Regulatory Agency; MNI: Montreal Neurological Institute; MRI: magnetic resonance imaging; NHS: The National Health Service; NMDA: N-methyl-D-aspartate; PANSS: The Positive and Negative Syndrome Scale; PIC: patient information centre; RA: research assistant; RMO: resident medical officer.

Competing interests
In the last three years, TREB has received honoraria for speaking at educational meetings and been a member of a scientific advisory board for Sunovion and Otsuka; PBJ has been a member of scientific advisory boards for Roche and Otsuka. SML has received personal fees from Jansen, Roche and Sunovion, and research grants from Abbvie, Roche and Pfizer. None of this funding was used to finance the present study or to cover the article processing charge. All the other authors declare no competing interest.

Authors’ contributions
DML designed compatible MRI experiments for all research centres involved in the study, trained all RAs in MRI procedures, designed MRI analysis and wrote the article. JS participated in designing of the study, supervised recruitment of participants and execution of the study at the University of Cambridge, supervised designing of the MRI experiment and critically revised the manuscript. TREP participated in designing of the study and critically revised the manuscript. IBC participated in designing of the study, supervised recruitment of participants and execution of the study at the Lancashire Early Intervention Services. PD participated in designing of the study, supervised recruitment of participants and execution of the study at the King’s College London. NH participated in designing of the study, supervised recruitment of participants and execution of the study at the Lancashire Early Intervention Services. PBJ provided advice on describing inflammation hypothesis in the article, participated in designing of the study and recruitment of participants at the University of Cambridge. EJ participated in designing of the study, designed the sessions measuring cognitive function of the participants, supervised recruitment of participants and execution of the study at the University College London and critically revised the manuscript. SML participated in designing of the study, supervised recruitment of participants and execution of the study at the University of Edinburgh. PJ critically revised the manuscript, supervised recruitment of participants and execution of the study at the University of Birmingham. BD conceived the study, participated in designing it, supervised the teams in all the research centres, supervised recruitment of participants and execution of the study at the University of Manchester and critically revised the manuscript. All authors read and approved the final manuscript.
Acknowledgements

The project is funded by the Efficacy and Mechanisms Evaluation (EME) Programme, an MRC and NIHR partnership (grant number 09/100/23). EMJ is supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. Minocycline and placebo are manufactured, controlled and distributed to the Trusts’ pharmacies by Catalent, UK. The authors would like to thank Dr Roger J Tait of the Behavioural and Clinical Neuroscience Institute (University of Cambridge) for his advice and insight on MRI analysis.

Disclaimer

The views expressed in this publication are those of the authors and not necessarily those of the MRC, NHS, NIHR or the Department of Health.

Author details

1Department of Psychiatry, Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK. 2Department of Psychiatry, Brain Mapping Unit, University of Cambridge, Herchel Smith Building for Brain and Mind Sciences, Robinson Way, Cambridge CB2 0SZ, UK. 3Cambridge and Peterborough NHS Foundation Trust, Cambridge, UK. 4Department of Medicine, Centre for Mental Health, Faculty of Medicine, Imperial College, London, UK. 5West London Mental Health NHS Trust, London, UK. 6Institute of Brain, Behaviour and Mental Health, Clinical and Cognitive Neurosciences, University of Manchester, Manchester, UK. 7Lancashire Care Early Intervention Service, Accrington, UK. 8Department of Psychiatry Studies, Institute of Psychiatry, King’s College, London, UK. 9Department of Psychiatry, University of Cambridge, Cambridge, UK. 10Institute of Neurology, University College London, London, UK. 11Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK. 12School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, UK. 13Early Intervention Service, Birmingham and Solihull Mental Health NHS Foundation Trust, Birmingham, UK. 14Manchester Mental Health and Social Care Trust, Manchester, UK.

Received: 2 December 2014 Accepted: 22 January 2015

References

1. Patterson TL, Kaplan RM, Grant I, Semple SJ, Moscona S, Koch WL, et al. Quality of well-being in late-life psychosis. Psychiatry Res. 1996;63:169–81.
2. Barnes TR, Leeson VC, Mutsatsa SH, Watt HC, Hutton SB, Joyce EM. Duration of untreated psychosis and social function: 1-year follow-up study of first-episode schizophrenia. Br J Psychiatry. 2008;193:203–9.
3. American Psychiatric Association, American Psychiatric Association. DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington, DC: American Psychiatric Association; 2013.
4. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertraline compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res. 1999;35:1–68.
5. Ho B-C, Nopoulos P, Rainm M, Arndt S, Andreasen NC. Two-year outcome in first-episode schizophrenia: predictive value of symptoms for quality of life. Am J Psychiatry. 1998;155:1196–201.
6. Drake RJ, Haley CJ, Akhtar S, Lewis SW. Causes and consequences of duration of untreated psychosis in schizophrenia. Br J Psychiatry. 2000;177:511–5.
7. Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry. 2005;62:975–83.
8. McGlashan TH. Duration of untreated psychosis in first-episode schizophrenia: marker or determinant of course? Biol Psychiatry. 1999;46:899–907.
9. Melle I, Larsen TK, Haahr U, Friis S, Johannesen JO, Ophoffroen SO, et al. Prevention of negative symptom psychopathologies in first-episode schizophrenia: two-year effects of reducing the duration of untreated psychosis. Arch Gen Psychiatry. 2008;65:334–40.
10. Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry. 2005;162:1785–804.
11. Waddington J, Youself H, Kinsella A. Sequential cross-sectional and 10-year prospective study of severe negative symptoms in relation to duration of initially untreated psychosis in chronic schizophrenia. Psychiat Res. 1995;5:25849–57.
12. Miyako T, Yasukawa R, Yasuda H, Hayashida M, Inagaki T, Hiroguchi J. Possible antipsychotic effects of minocycline in patients with schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry. 2007;31:304–7.
13. Miyako T, Wake R, Furuya M, Iaary K, Ieda M, Nakakami K, et al. Minocycline as adjunctive therapy for patients with unipolar psychiatric depression: an open-label study. Prog Neuro-Psychopharmacol Biol Psychiatry. 2012;37:222–6.
14. Chaudhry JB, Hallak J, Husain N, Minhas F, Strilting J, Richardson P, et al. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol. 2012;26:1185–93.
15. Levkovitz Y, Mendlovich S, Riwok S, B raw Y, Levkovitch-Velbin H, Gal G, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry. 2010;71:138.
16. Elewa H, Hiliil H, Hess DC, Machado LS, Fagan SC. Minocycline for short-term-term neuroprotection. Pharmacotherapy. 2008;26:515–21.
17. Strilting DP, Kouchesfahani RM, Stevenes JD, Tetzlaff W. Minocycline as a neuroprotective agent. Neuroscientist. 2005;11:308–22.
18. Wells JE, Hurlbert FE, Fehlings MG, Yong VW. Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain. 2003;126:1628–37.
19. Zhang W, Narayanan M, Friedlander RM. Additive neuroprotective effects of minocycline with creative in a mouse model of ALS. Ann Neural. 2003;53:267–70.
20. Savin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet. 1988;15:355–66.
21. Sakata H, Nizuma K, Yoshioke H, Kim GS, Jung JE, Katsu M, et al. Minocycline-preconditioned neural stem cells enhance neuroprotection after ischemic stroke in rats. J Neurosci. 2012;32:3462–73.
22. Koistinaho J, Koistinaho M. Minocycline, a tetracycline derivative, as a potential protective agent for acute stroke. In: Immunological mechanisms and therapies in brain injuries and stroke. New York Springer, 2014: p. 275–85.
23. Fan X, Lo EH, Wang X. Effects of minocycline plus tissue plasminogen activator combination therapy after focal embolic stroke in type I diabetic rats. Stroke. 2013;44:745–52.
24. Dixit A, Sivastava G, Verma D, Mishra M, Singh PK, Prakash O, et al. Minocycline, levodopa and MnTMPyP-induced changes in the mitochondrial proteome profile of MPTP and maneb and paraquat mouse models of Parkinson’s disease. Biochim Biophys Acta (BBA) - Mol Basis Dis. 2013;1832:1227–40.
25. Inamdar AA, Chauhduri A, D’Onofrio J. The protective effect of minocycline in a paraquat-induced Parkinson’s disease model in Drosophila is modified in altered genetic backgrounds. Park Dis. 2012;2012:1–16.
26. Kim H-S, Suh Y-H. Minocycline and neurodegenerative diseases. Behav Brain Res. 2009;196:168–79.
27. Whitford TJ, Grieve SM, Farow TF, Gomes L, Brennan J, Harris AW, et al. Progressive grey matter atrophy over the first 2–3 years of illness in first-episode schizophrenia: a tensor-based morphometry study. Neuroimage. 2006;32:511–9.
28. Chua SE, Cheung C, Cheung V, Tsang JT, Chen EY, Wong JC, et al. Cerebral grey, white matter and csf in never-medicated, first-episode schizophrenia. Schizophr Res. 2007;89:12–21.
29. Theberge J, Williamson K, Aoyama N, Drost DJ, Manchanda R, Malla AK, et al. Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. Br J Psychiatry. 2007;191:325–34.
30. Panteles C, Velakoulis D, McGorry PD, Wood SJ, Suckling J, Phillips LJ, et al. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet. 2003;361:281–8.
31. Malla AK, Bodnar M, Joobor R, Lepage M. Duration of untreated psychosis is associated with orbital-frontal grey matter volume reductions in first-episode schizophrenia. Schizophr Res. 2011;125:13–20.
32. Cahn W, Van Haen N, Pol HH, Schnack H, Carpers E, Lapperon D, et al. Brain volume changes in the first year of illness and 5-year outcome of schizophrenia. Br J Psychiatry. 2006;189:381–2.
33. Bastos LFS, Merlo LA, Rocha LTS, Coelho MM. Characterization of the antinociceptive and anti-inflammatory activities of doxycycline and minocycline in different experimental models. Eur J Pharmacol. 2007;576:171–9.
34. Wang J, Wei Q, Wang C-Y, Hill WD, Hess DC, Dong Z. Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria. J Biol Chem. 2004;279:19948–54.

35. Monji A, Kato T, Kanba S. Cytokines and schizophrenia: microglia hypothesis of schizophrenia. Psychiatri Schizophr Neurosci. 2009;63:257–65.

36. van Berckel BN, Boossing MG, Boellaard R, Klotz R, Schuitmaker A, Caspers E, et al. Microglia activation in recent-onset schizophrenia: a quantitative (<1×<10^6) decrease in CD11b+ phagocytic cells. Biol Psychiatry. 2008;64:820–2.

37. Paul-Samojedny M, Kowalczyk M, Suchanek R, Owczarek A, Fila-Danilow A, Szczygiel A, et al. Functional polymorphism in the interleukin-6 and interleukin-10 genes in patients with paranoid schizophrenia - a case-control study. J Mol Neurosci. 2010;42:112–9.

38. van Kemen M, McAllister C, Kelley M. Relationship between immune and behavioral measures in schizophrenia. Vienna: Springer; 1997.

39. Upthegrove R, Manzanezes-Teson N, Barnes NW. Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis. Schizophr Res. 2014;155:101–8.

40. Miller BJ, Buckley P, Seabolt W, Mello A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011;70:633–71.

41. Khandaker GM, Pearson RM, Zammit S, Lewis G, Jones PB. Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. JAMA Psychiatry. 2014;71:1211–8.

42. Olney JW, Newcomer JW, Farber NB. NMDA receptor hypofunction hypothesis of schizophrenia. J Psychiatr Res. 1999;33:523–33.

43. Hirota K, Lambert DG. Ketamine: its mechanism(s) of action and unusual behavior by minocycline in mice: possible involvement of antioxidant and nitrergic pathways. J Psychopharmacol. 2013;27:1032–52.

44. Choi SH, Lee DY, Chung ES, Hong YB, Kim SU, Jin BK. Inhibition of microglial activation and NADPH oxidase by minocycline protects dopaminergic neurons in the substantia nigra in vivo. J Neurochem. 2008;103:755–65.

45. Monte AS, de Souza GC, McIntyre RS, Soczynska JK, dos Santos J, Cordeiro RC, et al. Prevention and reversal of ketamine-induced schizophrenia related behavior by minocycline in mice: possible involvement of antioxidant and nitric pathway. J Psychopharmacol. 2008;65:154–64.

46. Newcomer JW, Farber NB, Jestevic-Todorovic V, Selke G, Nelson AK, Hershby T, et al. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology. 1999;20:106–18.

47. Choi SH, Lee DY, Chung ES, Hong YB, Kim SJ, Jin BK. Inhibition of thrombin-induced microglial activation and NADPH oxidase by minocycline protects dopaminergic neurons in the substantia nigra in vivo. J Neurochem. 2008;103:755–65.

48. Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology of schizophrenia. J Psychiatr Res. 1999;33:523–55.

49. Paul-Samojedny M, Kowalczyk M, Suchanek R, Owczarek A, Fila-Danilow A, Szczygiel A, et al. Functional polymorphism in the interleukin-6 and interleukin-10 genes in patients with paranoid schizophrenia - a case-control study. J Mol Neurosci. 2010;42:112–9.

50. van Kemen M, McAllister C, Kelley M. Relationship between immune and behavioral measures in schizophrenia. Vienna: Springer; 1997.

51. Upthegrove R, Manzanezes-Teson N, Barnes NW. Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis. Schizophr Res. 2014;155:101–8.

52. Miller BJ, Buckley P, Seabolt W, Mello A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011;70:633–71.

53. Khandaker GM, Pearson RM, Zammit S, Lewis G, Jones PB. Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. JAMA Psychiatry. 2014;71:1211–8.

54. Olney JW, Newcomer JW, Farber NB. NMDA receptor hypofunction hypothesis of schizophrenia. J Psychiatr Res. 1999;33:523–33.

55. Hirota K, Lambert DG. Ketamine: its mechanism(s) of action and unusual clinical use. 1996.

56. Deakin JW, Lees J, McKe S, Hallak JE, Williams SR, Dursun SM. Glutamate and the neural basis of the subjective effects of ketamine: a pharmacocognitive magnetic resonance imaging study. Arch Gen Psychiatry. 2008;65:154–64.

57. Newcomer JW, Farber NB, Jestevic-Todorovic V, Selke G, Nelson AK, Hershby T, et al. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology. 1999;20:106–18.

58. Choi SH, Lee DY, Chung ES, Hong YB, Kim SJ, Jin BK. Inhibition of thrombin-induced microglial activation and NADPH oxidase by minocycline protects dopaminergic neurons in the substantia nigra in vivo. J Neurochem. 2008;103:755–65.

59. Monte AS, de Souza GC, McIntyre RS, Soczynska JK, dos Santos J, Cordeiro RC, et al. Prevention and reversal of ketamine-induced schizophrenia related behavior by minocycline in mice: possible involvement of antioxidant and nitric pathways. J Psychopharmacol. 2008;65:154–64.

60. Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology of schizophrenia. J Psychiatr Res. 2001;158:367–77.

61. Lee J, Keener AP. Differential contribution of NMDA receptors in hippocampal subregions to spatial working memory. Nat Neurosci. 2002;5:162–8.

62. Lisman JE, Felliou S-M, Wang X-J. A role for NMDA-receptor channels in working memory. Nat Neurosci. 1998;1:273–5.

63. Correll RU, Hauser M, Aulter AM, Cornblatt BA. Research in people with schizophrenia. Psychiatri Clin Neurosci. 2009;63:257–65.

64. van Berckel BN, Boossing MG, Boellaard R, Klotz R, Schuitmaker A, Caspers E, et al. Microglia activation in recent-onset schizophrenia: a quantitative (<1×<10^6) decrease in CD11b+ phagocytic cells. Biol Psychiatry. 2008;64:820–2.

65. Paul-Samojedny M, Kowalczyk M, Suchanek R, Owczarek A, Fila-Danilow A, Szczygiel A, et al. Functional polymorphism in the interleukin-6 and interleukin-10 genes in patients with paranoid schizophrenia - a case-control study. J Mol Neurosci. 2010;42:112–9.

66. van Kemen M, McAllister C, Kelley M. Relationship between immune and behavioral measures in schizophrenia. Vienna: Springer; 1997.

67. Upthegrove R, Manzanezes-Teson N, Barnes NW. Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis. Schizophr Res. 2014;155:101–8.

68. Miller BJ, Buckley P, Seabolt W, Mello A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011;70:633–71.

69. Khandaker GM, Pearson RM, Zammit S, Lewis G, Jones PB. Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. JAMA Psychiatry. 2014;71:1211–8.

70. Olney JW, Newcomer JW, Farber NB. NMDA receptor hypofunction hypothesis of schizophrenia. J Psychiatr Res. 1999;33:523–33.

71. Hirota K, Lambert DG. Ketamine: its mechanism(s) of action and unusual clinical use. 1996.

72. Deakin JW, Lees J, McKe S, Hallak JE, Williams SR, Dursun SM. Glutamate and the neural basis of the subjective effects of ketamine: a pharmacocognitive magnetic resonance imaging study. Arch Gen Psychiatry. 2008;65:154–64.

73. Newcomer JW, Farber NB, Jestevic-Todorovic V, Selke G, Nelson AK, Hershby T, et al. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology. 1999;20:106–18.

74. Choi SH, Lee DY, Chung ES, Hong YB, Kim SJ, Jin BK. Inhibition of thrombin-induced microglial activation and NADPH oxidase by minocycline protects dopaminergic neurons in the substantia nigra in vivo. J Neurochem. 2008;103:755–65.
88. Dinarello CA. The interleukin-1 family: 10 years of discovery. FASEB J. 1994;8:1314–25.
89. Carr MW, Roth SJ, Luther E, Rose SS, Springer TA. Monocyte chemotactic protein 1 acts as a T-lymphocyte chemotactic protein. Proc Natl Acad Sci. 1994;91:3652–6.
90. Koenig W, Sund M, Fröhlich M, Fischer H-G, Löwel H, Döring A, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999;99:237–42.
91. Emsley R, Dunn G, White IR. Mediation and moderation of treatment effects of instrumental variable methods. Stat Methods Med Res. 2005;14:369–90.
92. Emsley HC, Smith CJ, Svendsen F, Carlsson CM, Georgiou RF, Vail A, Barberan EM, et al. Clinical outcome following acute ischaemic stroke relates both to activation and autoregulatory inhibition of cytokine production. BMC Neurol. 2007;7, 5.
93. Holt I, Cooper R, Denton J, Meager A, Hopkins S. Cytokine inter-relationships and their association with disease activity in arthritis. Rheumatology. 1992;31:275–33.
94. Zhang J, Tong L, Wang L, Li N. Texture analysis of multiple sclerosis: a comparative study. Magn Reson Imaging. 2008;26:1160–6.
95. Klingberg T, Olesen J, Kristoffersen H, Frisch B. Bilateral activation of fronto-parietal networks by increasing demand in a working memory task. Cereb Cortex. 1997;7:745–71.
96. Fransson P, Marrelec G. The precuneus/posterior cingulate cortex plays a pivotal role in the default mode network: evidence from a partial correlation network analysis. Neuroimage. 2008;42:1178–84.
97. Greicius MD, Krasnow B, Reiss AL, Menon V. Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proc Natl Acad Sci. 2003;100:253–8.
98. Barnes A, Bullmore ET, Suckling J. Endogenous human brain dynamics recover slowly following cognitive effort. PLoS One. 2009;4:e6626.
99. Owen AM, McMillan KM, Laird AR, Bullmore E. N-back working memory paradigm: a meta-analysis of normative functional neuroimaging studies. Hum Brain Mapp. 2005;25:46–59.
100. Jack CR, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, et al. The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008;27:685–91.
101. Addington D, Addington J, Matos-Tyndale E. Specificity of the Calgary Depression Scale for schizophrenics. Schizophr Res. 1994;11:239–44.
102. Simpson G, Angus J. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand. 1970;45:11–9.
103. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;155:472–6.
104. Lane RD, Glazer WM, Hansen TE, Berman WH, Kramer SJ. Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale. J Nerv Ment Dis. 1985;173:353–7.
105. Yusufi B, Mukherjee S, Atchison K, Dunn G, Page A, Barnes T. Reliability of the antipsychotic non-neuroleptic side effects rating scale (ANNERS). J Psychopharmacol. 2005;19:A10.
106. Hayward P. Medication self-management: a preliminary report on an intervention to improve medication compliance. J Ment Health. 1996;5:611–8.
107. Everitt B, Pickles A. Statistical aspects of the design and analysis of clinical trials. London: World Scientific; 2004.
108. Heyting A, Tolboom J, Essers J. Statistical handling of drop-outs in longitudinal clinical trials. Stat Med. 1992;11:2043–61.
109. Dunn G, Maracy M, Dowrick C, Ayuso-Mateos JL, Dalgaard O, Page H, et al. The Outcomes of Depression International (ODIN) Group (2003). Estimating psychological treatment effects from an RCT with both non-compliance and loss to follow-up. Br J Psychiatry. 2003;183:323–31.
110. Dunn G, Maracy M, Tomenson B. Estimating treatment effects from randomized clinical trials with noncompliance and loss to follow-up: the role of instrumental variable methods. Stat Methods Med Res. 2005;14:369–95.
111. Emsley R, Dunn G, White IR. Mediation and moderation of treatment effects in randomised controlled trials of complex interventions. Stat Methods Med Res. 2010;19:237–70.
112. Jenkinson M, Smith S. A global optimisation method for robust affine registration of brain images. Med Image Anal. 2001;5:143–56.
113. Douaud G, Smith S, Jenkinson M, Behrens T, Johansen-Berg H, Vickers J, et al. Anatomically related grey and white matter abnormalities in adolescent-onset schizophrenia. Brain. 2007;130:2375–86.
114. De Stefano N, Matthews P, Filippi M, Agosta F, De Luca M, Bartolozzi M, et al. Evidence of early cortical atrophy in MS Relevance to white matter changes and disability. Neurology. 2003;60:1157–62.
115. Zarahn E, Aguirre GK, D’Esposito M. Empirical analyses of BOLD fMRI statistics. Neuroimage. 1997;5:179–97.
116. Suckling J, Ohlsson D, Andrew C, Johnson G, Williams SC, Graves M, et al. Components of variance in a multicentre functional MRI study and implications for calculation of statistical power. Hum Brain Mapp. 2008;29:1111–22.
117. Mori S, Watanabe S, Van Zijl PC, Nagae-Poetscher L. MRI atlas of human white matter. 2005.
118. Rissman J, Gazzaley A, D’Esposito M. Measuring functional connectivity during distinct stages of a cognitive task. Neuroimage. 2004;23:752–63.
119. Winkler AM, Ridgway GR, Webster MA, Smith SM, Nichols TE. Permutation inference for the general linear model. Neuroimage. 2014;92:381–97.